Dr. McGregor on Advances Made in the Adjuvant Setting of RCC

Video

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Four trials have investigated the use of TKIs in the adjuvant setting, including the ASSURE trial comparing sunitinib (Sutent) with sorafenib (Nexavar), which showed no difference in progression-free survival (PFS) or overall survival (OS). Additionally, there was the ATLAS trial, which looked at axitinib (Inlyta) versus placebo, and showed no difference in PFS or OS. Data from the PROTECT trial with pazopanib (Votrient) showed no difference in OS or PFS. However, the S-TRAC trial, which looked at very high-risk patients, showed that 1 year of sunitinib resulted in an improvement in disease-free survival. However, no benefit in OS has been reported yet, says McGregor. Even so, this may be a suitable option for patients who are able to tolerate its side effect profile, he adds.

The PROSPER trial is a perioperative study of nivolumab (Opdivo), in which patients receive neoadjuvant nivolumab followed by adjuvant nivolumab versus observation. There are also localized trials looking at pembrolizumab (Keytruda) versus placebo and atezolizumab (Tecentriq) versus placebo. Since these are placebo-controlled trials, counseling patients on whether or not to enroll should be a nuanced discussion, says McGregor.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute